Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + topotecan
- Development stage
- Unknown
- Lead developer
- Fox Chase Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination chemotherapy regimen consists of paclitaxel, carboplatin, and topotecan, and was specifically evaluated by the Fox Chase Cancer Center in a Phase II clinical trial. The protocol involves the administration of high-dose chemotherapy followed by peripheral blood stem cell (PBSC) transplantation to rescue the bone marrow from severe myelosuppression. Paclitaxel acts as a microtubule-stabilizing agent that inhibits mitosis, carboplatin is a platinum-based DNA alkylating agent that induces apoptosis through DNA cross-linking, and topotecan is a topoisomerase I inhibitor that causes lethal DNA strand breaks. This intensive approach was designed to treat extensive-stage small cell lung cancer (SCLC) and carcinoma of unknown primary, aiming to overcome drug resistance in metastatic settings.
- Other names
- High-dose paclitaxel, carboplatin, and topotecan with PBSC supportPaclitaxel-Carboplatin-Topotecan combination
02
Targets
TOP1 (DNA Topoisomerase I)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on paclitaxel + carboplatin + topotecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + topotecan.